Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2024-06-20 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Syncona adds two oncology companies to portfolio
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 1278T' and contains standard boilerplate language referencing RNS, the news service of the London Stock Exchange, and the Financial Conduct Authority. The content announces significant corporate actions: Syncona leading a Series B financing in iOnctura and launching a new company, Yellowstone, with a Series A commitment. This type of immediate, material corporate news release disseminated via an official regulatory channel (RNS) fits best under the general 'Regulatory Filings' category, as it is not a full financial report (10-K, IR), an earnings release (ER), a proxy statement (DEF 14A), or a specific transaction report like Director's Dealing (DIRS) or Share Repurchase (POS). It is a general regulatory announcement.
2024-06-20 English
Final Results
Annual Report Classification · 1% confidence The document is titled 'Full Year Results for the 12 months ended 31 March 2024' and is issued by Syncona Limited. It contains comprehensive financial performance data, including Net Asset Value (NAV) calculations, portfolio valuations, and management commentary on the fiscal year. While it is an RNS-distributed announcement, it serves as the primary disclosure of the company's annual financial results, fitting the definition of an Annual Report (10-K) or a comprehensive annual financial disclosure. FY 2024
2024-06-20 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document explicitly announces a 'Transaction in Own Shares' as its subject. It details the date of purchase, the aggregate number of ordinary shares purchased (140,000), the price paid, and the resulting change in the total voting rights. This directly corresponds to the definition of a company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' filing type.
2024-06-20 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document explicitly announces a 'Transaction in Own Shares' under a previously announced 'share buyback programme'. It details the date of purchase, the aggregate number of shares purchased, and the price paid. This directly corresponds to the definition of a Transaction in Own Shares (share repurchase/issuance). The presence of the RNS Number and the closing statement confirming the information is provided by RNS (the news service of the London Stock Exchange) confirms it is a regulatory announcement, but the specific content points overwhelmingly to the 'POS' category over the general 'RNS' fallback.
2024-06-19 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document explicitly states the subject is 'Transaction in Own Shares' and details the purchase of 60,000 ordinary shares as part of a 'share buyback programme'. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS), which covers company share repurchases. The presence of the RNS Number and the closing statement confirming the information is provided by RNS (the news service of the London Stock Exchange) confirms it is a regulatory disclosure, but the specific content points overwhelmingly to POS.
2024-06-18 English
Creation of Spur Therapeutics
M&A Activity Classification · 1% confidence The document begins with 'RNS Number : 7173S' and contains contact information referencing 'RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This strongly indicates a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details a corporate action: the acquisition of SwanBio by Freeline to create Spur Therapeutics, including financial commitments and pipeline updates. This type of material announcement, which is not a full financial report (like 10-K or IR) or a specific shareholder vote result, fits best under the general regulatory announcement category, RNS, as it is a material event disclosure.
2024-06-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.